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1. Introduction 
Metabolic syndrome is a cluster of abnormalities that are often associated with prediabetes, 
a condition present prior to the onset of diabetes (1). The hallmark of both metabolic 
syndrome and prediabetes is insulin resistance, an impairment of insulin action within 
tissues at the level of the insulin receptor and subsequent cellular events. Insulin resistance 
resides mainly within muscle, liver and adipose tissues (2). Type 2 diabetes arises from a 
combination of insulin resistance and a relative impairment of insulin secretion in response 
to meal ingestion. Type 2 diabetics differ in the relative contributions of insulin resistance 
and impaired insulin secretion to the development of hyperglycemia (3). Some diabetic 
patients predominantly have a secretory defect, while others may have normal or even 
excessive insulin secretion. The latter subgroup of diabetics has insulin resistance as the 
primary defect in their glucose homeostasis. Hyperglycemia by itself does not indicate 
whether there is an insufficiency of insulin secretion or a deficit in insulin action. Type 2 
diabetics lie along a continuum between these two extremes, with a variable mix of 
secretory and cell signaling deficits. During the progression from normal glucose tolerance 
to impaired glucose tolerance to prediabetes to diabetes to severe diabetes over a number of 
years, individuals show a progressive decline in pancreatic insulin secretion in response to a 
glucose load(3). Insulin resistance may show progressive deterioration, but generally insulin 
resistance is the major defect early in the development of diabetes whereas late in the course 
of the disease pancreatic islet cell failure is more notable. 
In Type 2 diabetes, determining the relative contribution of insulin secretion versus action 
has clinical implications. Knowledge of the predominant abnormalities in glucose 
homeostasis may well affect the choice of therapeutic agent for the treatment of diabetes. For 
example, metformin acts to reduce insulin resistance, particularly within the liver (4), and 
therefore is of considerable utility in early stages of Type 2 diabetes where insulin resistance 
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is predominant. Sulfonylureas such as glyburide, in contrast, promote the secretion of 
endogenous insulin in response to a meal (5) and might therefore be more useful when 
insulin secretion is declining.  
However, some have alleged that sulfonylureas may accelerate beta cell exhaustion over 
time and thereby accelerate the deterioration of diabetes (5). The incretin mimetic agents 
such as exendin and the DPP-IV inhibitors also promote insulin release from pancreatic 
islets but may also be cytoprotective within pancreatic islets and thereby delay the 
progression of diabetes (6). As shown in the Results section below, DPP-IV inhibitors are 
also effective in reversing metabolic syndrome prior to the onset of diabetes. 
Diabetes typically manifests itself in the context of other abnormalities, especially the 
principal components of metabolic syndrome, namely hypertension and hyperlipidemia (2). 
The SHROB or Koletsky rat is a leading animal model of metabolic syndrome (7;8), as 
summarized in Table 1.  
 
Trait SHR(7) SHROB(7) Human Metabolic 
Syndrome(9) 
Hypertension SBP = 195 SBP = 185 SBP > 130 
Insulin resistance Absent Profound Present 
Fasting glucose Normal Normal to slightly 
high 
Normal to slightly 
high 
Glucose tolerance Normal Impaired Impaired 
Triglycerides Absent >200 mg/dL >150 mg/dL 
Total Cholesterol Normal Slightly elevated >200 mg/dL 
Visceral obesity Absent Present Present 
Fasting insulin Normal Elevated 20-fold Elevated 
Fasting glucagon Normal(10) Elevated 2-fold(10) Elevated(11;12) 
Table 1. Characteristics of human metabolic syndrome compared with the SHROB model 
Each of the primary abnormalities expressed in human metabolic syndrome are present in 
the SHROB rat. Other obese rodents fail to show these characteristics. In particular, the 
SHROB is only rodent model that incorporates hypertension and related cardiovascular 
changes together with insulin resistance and abnormal glucose homeostasis. The SHROB 
has marked hyperinsulinemia without hyperglycemia. Other rodent models show diabetes 
that ranges from mild (Zucker fatty rat) to fulminant Type 2 diabetes (db/db mouse) (8;13).  
In contrast, the SHROB is a model for the prediabetic state accompanied by hypertension 
and hyperlipidemia as well as obesity. Prediabetes can lead to secondary disease 
complications even in the absence of fasting hyperglycemia (14). The SHROB model can be 
used to understand the complex physiologic processes that contribute to metabolic 
syndrome. Dietary and pharmacologic interventions in this model may help identify the 
best prevention strategies and treatment combinations for metabolic syndrome as well. 
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Premise: The oral glucose tolerance test (OGTT) is vital for the characterization of metabolic 
syndrome, the natural progression from prediabetes to Type 2 diabetes, and characterization 
of the metabolic actions of cardiovascular and metabolic drugs. Although the OGTT is 
seldom used as a diagnostic test for Type 2 diabetes (15), it is extensively used as a sensitive 
indicator of gestational diabetes (16). As we demonstrate in the present work, the OGTT is 
an important laboratory tool in preclinical studies. In both humans and animals, the OGTT 
provides an indication of the relative roles of insulin secretion and insulin resistance in the 
progression of glucose intolerance. The impact of diet composition and pharmacologic 
interventions can be tested and possible target tissues identified. This in vivo, real time, 
whole body test can be used to identify the best treatments and possibly delay or prevent 
development of Type 2 diabetes. 
Insulin release in response to a glucose load occurs in two phases in humans and in rodents. 
The early phase peaks within the first 15-30 min and is responsible for limiting the initial 
rise in glucose upon meal ingestion. The late phase of insulin secretion occurs later than 30 
min after a meal, and may persist for several hours. This delayed burst of insulin secretion is 
responsible for returning glucose to baseline fasting levels. In the face of insulin resistance, 
the late phase of insulin secretion persists for an extended period and contributes to 
excessive insulin levels even after a return to the fasted state, resulting in fasting 
hyperinsulinemia (2). 
Insulin and glucagon, derived from beta and alpha pancreatic islet cells, respectively, are the 
two most important hormones involved in glucose homeostasis. Together they determine 
whether food is utilized immediately for energy or put into storage for later use. 
Abnormalities in the release or actions of either or both of these hormones can be involved 
in the development of hyperglycemia and diabetes. Glucagon levels may influence glucose 
tolerance (11), although this hormone is seldom considered in the context of oral glucose 
tolerance. Glucagon raises glucose levels, and a higher level of insulin is needed to control 
glucose in the presence of glucagon (10). 
 The phases of insulin secretion in response to the oral ingestion of glucose are cephalic, 
gastric and intestinal. The cephalic phase begins with the sight of food and is strongly 
triggered by sweet taste receptors on the tongue (17). The cephalic and gastric phases are 
considered part of the early response, while the intestinal response is later. Interestingly, 
sweet taste receptors are also present in the small intestine and may shape the physiological 
response to carbohydrates (18;19). Sweet taste receptors in the small intestine not only 
regulate the rate of glucose absorption through glucose transporters (19), but also trigger the 
release of GLP-1 and cholecystokinin (18). GLP-1 and gastric inhibitory peptide (GIP) are 
incretins, gut hormones secreted from enteroendocrine cells into the blood in response to 
meal ingestion. Importantly, incretin secretion only occurs with oral ingestion of nutrients. 
Incretin secretion is not triggered in response to intravenous feeding, as the intestinal 
receptors are not activated when glucose is delivered through the circulation. Indeed, 
incretins were discovered as a result of the observation that the insulin stimulation and 
glucagon suppression by glucose was much greater when glucose was delivered orally or 
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into the gut rather than by any other route (20). Thus, the normal physiological response to 
food ingestion can only be elicited through the oral route of administration. 
Both incretins are rapidly deactivated by a degradative enzyme called dipeptidyl peptidase 
4 (DPP4) (21). Since 2005, two new classes of drugs based on incretin action have been 
approved for Type 2 diabetes therapy: incretin analogs and incretin enhancers, which inhibit 
DPP4. DPP4 inhibitors act by slowing the breakdown of endogenous incretin peptides, thus 
extending their actions. 
An OGTT is used clinically to diagnose impaired glucose tolerance and as a standardized 
test of carbohydrate metabolism and insulin secretion. The test is based on oral 
administration of glucose and subsequently following plasma glucose and insulin levels 
over time. A prolonged elevation (>120min) in both plasma glucose and insulin constitutes 
impaired glucose tolerance and insulin resistance and can be used in conjunction with 
fasting hyperglycemia in diagnosing Type 2 diabetes. A prolonged elevation in glucose with 
minimal changes in insulin secretion would be suggestive of impaired glucose stimulated 
insulin secretion. This procedure is directly applicable to rats and mice. 
The OGTT was introduced first as a diagnostic tool for diabetes. Later studies focused on 
identifying patterns of the glucose curve during the OGTT that predicted the onset of 
diabetes years later. An OGTT profile during pregnancy can accurately predict which 
women will later develop Type 2 diabetes when they reach middle age (22). Clinically, the 
use of OGTT has fallen off because of the need for glucose loading, which many patients 
perceive as unpleasant. Furthermore, 4 to 6 separate blood samples are necessary. In the 
modern clinic, the OGTT has generally been supplanted by measuring fasting blood 
glucose, random post prandial blood glucose and glycosylated hemoglobin values. 
The OGTT is influenced by many factors including age, diet, state of health, GI function, 
medications and emotional state. As age increases, the excursion of glucose during the 
OGTT progressively increases as a consequence of declining insulin sensitivity of target 
tissues, such as in muscle, fat and liver. The dose of glucose and standardization of 
measured responses including glucose levels and insulin have been debated over the years. 
When used in large population studies the OGTT test overestimates the prevalence of 
diabetes. In other words, it has a high false positive rate. 
The intravenous glucose tolerance test is not sensitive for the diagnosis of diabetes and is 
used mainly as an assessment purely of glucose disposal i.e. the time required for glucose to 
clear circulation. It can be used as an index of residual beta cell function as well. The test 
bypasses the GI tract and eliminates the influence of intestinal hormones, especially 
incretins, on insulin and glucagon levels and subsequent glucose disposal. The endocrine 
system of the small intestine is important in the development of diabetes and has spawned 
new drugs to treat diabetes. The relative advantages of OGTT over other methods of 
assessing glucose homeostasis in the laboratory are summarized in Table 2. 
The hyperinsulemic clamp has been described by some authors as “the gold standard” yet 
has a number of limitations. Indwelling catheters are required, necessitating some trauma. 
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Even with time for recovery, glucose homeostasis can be altered by ongoing wound healing 
and pain. For highly insulin resistant individuals, insulin must be elevated to very high 
levels. For example, insulin levels in SHROB rats must be raised to levels that would result 
in convulsions and death from hypoglycemia in a lean animal (results not shown). The 
OGTT allows all of the normal stages of insulin secretion and glucose processing to take 
place in sequence without causing stress or trauma to the subject. 
 
 OGTT IVGTT Hyperinsulinemic 
Clamp 
Incorporates cephalic phase Yes No No 
Incorporates gut-pancreatic axis Yes No No 
First pass through liver and portal circulation Yes No No 
Raises insulin to nonphysiologic levels No No Yes 
Requires surgery No Yes Yes 
Table 2. Advantages of OGTT over IVGTT and hyperinsulinemic clamps 
2. Methods  
Special diets are fed for 30 to 90d prior to the OGTT. Antihypertensive or antidiabetic 
medications are given in the drinking water or incorporated into the food and given for 42 
to 90d. We carry out the OGTT by fasting animals for 18h, taking a baseline 200 µL blood 
sample from the tail under local anesthesia, and then gavaging with 12 mL/kg of a 50% 
glucose solution, which delivers 6g of glucose per kg of body weight. Blood samples are 
taken 30, 60, 120, 180, 240 and 360 minutes after the glucose meal and analyzed for blood 
glucose with a clinical meter. Plasma samples are frozen for later analysis of rat insulin by 
ELISA. The 240 and 360 minute time points are not typically used in OGTT, but the SHROB 
is so profoundly glucose intolerant that extended sampling is required to reliably establish 
the area under the curve. Area under the curve is determined for each subject using curve 
fitting software (Prism 5.0, GraphPad software, San Diego, CA).  
Procedures: 
1. Weigh the rats to the nearest 0.5g and place them into clean cages with new bedding. 
Rodents are copraphagic, so new cages will assure true fasting conditions over the next 
18h.  
2. Dextrose (D-glucose) solution: A 50% dextrose solution is made by weighing out the 
needed amount of dextrose and heating and stirring with water (be sure not to overheat 
solution or caramelization will take place). For example, if you need 50mL of workable 
solution, you would weigh out 25g of dextrose and add that to approximately 28mL of 
water then stir and heat until dextrose is in solution. Once in solution, pour into a 
graduated cylinder and dilute up to 50mL and allow cooling at room temperature prior 
to using. 
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3. Dose: We administer a 6g/kg body weight of a 50% dextrose solution for our studies to 
assure a significant challenge to glucose metabolism, but 2-4g/kg body weight is 
frequently reported by others. 
4. Oral gavaging: Discharge rate should be slow so as not to cause a pressure induced 
“dumping syndrome”. This will be apparent about 30-60min after gavaging with the 
presence of diarrhea.  
5. Blood Collection: This is done by tail bleed. We recommend that blood be collected at 
least five times: 0, 30, 60, 120 and 180 min. However, we collect additional time points 
of 240 and 360 min in our SHROB rats, as this represents the delayed insulin peak 
response and allows an accurate estimate of the area under the curve for glucose, as 
glucose returns to fasting levels only very slowly. We also dip the cut tail tip into the 
local anesthetic, bupivacaine (Marcaine, 0.5%), after the first tail bleed and after each 
sample thereafter to minimize pain associated with the procedure. 
6. Glucose measurement: A clinical glucose meter (One Touch Ultra, Lifescan) is used 
with 5 µL of whole blood. 
7. Insulin and glucagon ELISA: Rodent-specific kits are available from several suppliers, 
including ALPCO (Salem, NH). The coefficient of variation is less than 10% in repeat 
measures and the sensitivity is 0.1 ng/mL. Plasma samples from our insulin resistant 
rats must be diluted 1:10 in assay buffer before addition to the assay plate. 
8. Statistical analysis: Glucose and insulin data are processed through an analysis of 
variance with repeated measures to determine treatment effects, time effects, and 
treatment by time interaction terms by using the Prism 5.0 statistical and graphing 
program (GraphPad Software, Sand Diego, CA). Newman-Keuls post-hoc tests are used 
to determine significance of individual comparisons. Area under the curve 
measurement are also determined for each animal, expressed as mg*min/dL for glucose 
and ng*min/mL for insulin, and analyzed as a single datum. 
3. Results 
We review data from several contrasting interventions in SHROB rats, which includes diets 
and drug treatments with both beneficial and harmful effects on glucose tolerance. We 
contrast the use of OGTT with other measures such as fasting glucose and glucose to insulin 
ratios.  
A relatively normal OGTT profile is illustrated by the data from lean SHR. Glucose starts at 
a low fasting level and rises only to a maximum of about 100 mg/dL at 60 min. Insulin levels 
are low in the fasted state and show a maximum 4-fold rise around 60 min and then return 
to baseline by 240 min. Not shown is the profile for normotensive Wistar or Sprague-
Dawley control rats, which would show a similar profile but with even lower levels of 
insulin owing to a small amount of insulin resistance associated with hypertension (23).  
SHROB on a control diet show a normal fasting level of glucose, but glucose ascends to a 
much higher peak around 60 min and takes much longer to return to baseline. Fasting 
insulin levels in the SHROB are 40-fold elevated compared to lean SHR littermates, and the 
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further rise in insulin in response to a glucose load is delayed and prolonged. Dietary obese 
genetically lean SHR rats are only about 25% overweight compared to lean SHR on normal 
chow, in contrast to genetically obese SHROB which are about 100% overweight compared 
to lean SHR on normal chow (24). Despite the lesser degree of obesity, the dietary obese 
genetically lean SHR showed about the same degree of glucose intolerance as SHROB. 
Insulin levels at fasting and after the glucose load were unchanged relative to the SHR fed 
control diet. SHROB fed a high sucrose diet showed unchanged glucose tolerance. In 
contrast, the insulin response to a glucose load was greatly increased and prolonged beyond 
that observed for SHROB on a control diet. To our knowledge, the insulin levels in sucrose-
fed SHROB during the OGTT, which exceed 100 ng/mL, are the highest ever recorded in a 
rodent. The data in Figure 1 illustrate the value of the OGTT. High sucrose input affected 
glucose levels in genetically lean animals without affecting insulin. In contrast, in genetically 
obese SHROB rats, high sucrose affected insulin without affecting glucose levels. None of 
this could be learned by obtaining fasting levels alone. 
 
Figure 1. Glucose tolerance test: SHR versus SHROB on normal versus high sucrose diets. A: Glucose. 
B: Insulin. SHR were fed a supplementary sweet drink to induce dietary obesity in these genetically 
lean rats. SHROB were fed a high sucrose diet (70% sucrose by weight).  
Figure 2 includes only the genetically obese SHROB fed a control diet, which were given 
vehicle or drug in their drinking water. Two oral antihyperglycemic agents, the insulin 
secretagogue glyburide (mg/kg) and the DPP4 inhibitor sitagliptin (mg/kg), were contrasted 
with the widely used antihypertensive hydrochlorothiazide (50 mg/kg). None of the agents 
had any effect on fasting glucose. The two antihyperglycemic agents, as expected, lowered 
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the excursion of glucose in response to an oral load. The antihypertensive agent 
dramatically increased glucose levels following the oral load, with glucose rising to levels 
associated with frank diabetes (>400 mg/dL).  
 
Figure 2. Glucose tolerance test: untreated SHROB versus SHROB treated with antihyperglycemic 
agents and one antihypertensive agent. A: Glucose. B: Insulin 
Fasting insulin levels in vehicle controls (Figure 2) were very high, similar to those observed 
before in Figure 1. The oral antihyperglycemic drugs both reduced fasting insulin levels, 
although not to levels seen in lean SHR. Remarkably, hydrochlorothiazide further elevated 
fasting insulin. The post-load insulin curve in glyburide treated SHROB closely paralleled 
vehicle treated controls, but at a lower level. The insulin curve for the sitagliptin treated 
group showed a higher net response to the glucose load, especially at 30 min. This is 
consistent with the hypothesized role of incretin hormones in facilitating the insulin 
response to glucose. Hydrochlorothiazide greatly increased insulin levels, reminiscent of the 
effect of dietary sucrose in Figure 1.  
Other hormones and metabolites can be measured during OGTT, not just glucose and 
insulin. Figure 3 illustrates changes in plasma glucagon during the first hour after an oral 
glucose load. Homeostasis predicts that glucagon would be high in the fasting state and 
decline when the fed state is restored. Glucagon levels are unchanged in SHR animals, 
possibly because the fall in glucagon is mainly mediated by gut hormones such as GLP-1 
and GIP which are secreted later after the load has reached the distal small intestine where 
the L-cells that secrete these hormones reside. Remarkably, SHROB rats show a dramatic 
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increase in glucagon from already high fasting levels. This paradoxical increase in glucagon 
in response to a glucose meal has been reported in humans with Type 2 diabetes (12). 
 
Figure 3. Changes in plasma glucagon level during an OGTT in SHROB and lean SHR littermates.  
Besides glucose, another plasma substrate that can be assayed is the level of free fatty acids. 
We found that free fatty acids fall after glucose load in lean SHR, indicating reduced 
lipolysis when an abundant supply of glucose is present (10). Remarkably, the level of free 
fatty acids in SHROB rats stayed at the elevated level found in fasting (data not shown). This 
finding illustrates the multiple abnormalities in the whole body handling of metabolic fuels 
that can be uncovered in an OGTT.  
4. Discussion 
These data show that OGTT is much more sensitive than are other measures in identifying 
the loci of insulin resistance and its modulation by different interventions. Moreover, the 
results of OGTT testing in the SHROB model tracks closely with efficacy against metabolic 
syndrome and Type 2 diabetes in clinical trials. Thus, the OGTT yields laboratory data with 
greater relevance to the prevention and treatment of human disease. 
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The glucose tolerance test determines the rate at which glucose is cleared from blood. 
Glucose is administered either orally or intravenously and serial samples of glucose, insulin 
and glucagon are measured over time. Hypoglycemic medications used to treat diabetes 
have been developed that modify the actions of glucagon and insulin directly. Medications 
that are used to treat high blood pressure and lipid disturbances can also modify the 
responses to these hormones, sometimes improving the clearance of glucose and sometimes 
making it worse. Comparisons of the responses of glucose, insulin and glucagon levels 
during glucose tolerance testing with and without medications used to treat metabolic 
syndrome will lead to a better understanding of what combinations of these medications are 
the most beneficial and least toxic. 
The current literature has many examples of inadequate assessments of glucose metabolism. 
Many authors report only on “random glucose” values, taken without regard to whether the 
animal had just eaten or had voluntarily fasted for several hours. If food is available ad 
libitum, then some animals may be postprandial and others will be fasted as a result of their 
sleep cycle. The glucose and insulin values obtained under these circumstances are highly 
variable and often irreproducible. A somewhat better approach is to determine fasting 
glucose and insulin levels. Various ratios between glucose and insulin can be calculated, 
with the most popular being the Homeostasis Model Assessment (HOMA). The 
mathematical derivation of the HOMA equation is sophisticated, but it is still based on only 
two numbers: fasting glucose and fasting insulin. The OGTT, by contrast, reflects the in vivo 
physiological response to a glucose meal and integrates the homeostatic response to a meal 
over time. Thus, the OGTT more accurately mirrors daily life. 
The OGTT is useful as a research tool. It does allow for a more physiologic assessment of 
metabolism as it assesses a global response to the disposition of a meal. Neurologic and 
hormonal responses that influence the function of the gastric tract, absorption, 
transportation and processing of food in the liver and transport to and from storage tissue 
can be assessed. These include newly recognized hormones secreted from the GI tract in the 
presence of food known as incretins and previously recognized hormones such as insulin 
and glucagon. The OGTT is particularly useful in characterizing the actions of drugs which 
can be either beneficial or detrimental to glucose homeostasis. 
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